Comparing of Kura Oncology Inc. (KURA) and INSYS Therapeutics Inc. (NASDAQ:INSY)

Kura Oncology Inc. (NASDAQ:KURA) and INSYS Therapeutics Inc. (NASDAQ:INSY) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Kura Oncology Inc. N/A 0.00 60.45M -1.67 0.00
INSYS Therapeutics Inc. 82.08M 4.15 124.51M -1.60 0.00

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of Kura Oncology Inc. and INSYS Therapeutics Inc.


Table 2 provides Kura Oncology Inc. and INSYS Therapeutics Inc.’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Kura Oncology Inc. 0.00% -44.8% -39.5%
INSYS Therapeutics Inc. -151.69% -362% -50.8%

Volatility and Risk

Kura Oncology Inc. has a 2.91 beta, while its volatility is 191.00%, thus making it more volatile than S&P 500. INSYS Therapeutics Inc.’s 156.00% more volatile than S&P 500 which is a result of the 2.56 beta.


Kura Oncology Inc.’s Current Ratio is 14.8 while its Quick Ratio is 14.8. On the competitive side is, INSYS Therapeutics Inc. which has a 0.7 Current Ratio and a 0.6 Quick Ratio. Kura Oncology Inc. is better positioned to pay off short and long-term obligations compared to INSYS Therapeutics Inc.

Analyst Recommendations

The next table highlights the shown recommendations and ratings for Kura Oncology Inc. and INSYS Therapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Kura Oncology Inc. 0 0 0 0.00
INSYS Therapeutics Inc. 1 0 3 2.75

INSYS Therapeutics Inc. on the other hand boasts of a $7.75 average price target and a 69.21% potential upside.

Institutional and Insider Ownership

Roughly 84% of Kura Oncology Inc. shares are owned by institutional investors while 18.9% of INSYS Therapeutics Inc. are owned by institutional investors. Insiders owned roughly 11.7% of Kura Oncology Inc.’s shares. On the other hand, insiders owned about 63.83% of INSYS Therapeutics Inc.’s shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Kura Oncology Inc. -2.2% -5.16% 22.4% -20.84% -32.98% 7.41%
INSYS Therapeutics Inc. 0.95% 83.82% 2.42% -20.1% -13% 81.71%

For the past year Kura Oncology Inc. was less bullish than INSYS Therapeutics Inc.

Kura Oncology, Inc., a clinical stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The companyÂ’s lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, lower risk myelodysplastic syndromes, and chronic myelomonocytic leukemia. It also develops KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment for patients with tumors that have mutations in, or other dysregulation of, the mitogen-activated protein kinase; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia. The company was founded in 2014 and is headquartered in La Jolla, California.

Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States. Its lead product candidate is SYNDROS, an orally administered liquid formulation of dronabinol for treating CINV and anorexia associated with weight loss in patients with AIDS. The company is also developing Cannabidiol Oral Solution, a synthetic cannabidiol for childhood catastrophic epilepsy syndromes; and other product candidates, including other dronabinol line extensions and sublingual spray product candidates. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.